Cardiac Pathways President and CEO Thomas Prescott is Interviewed by the Wall Street Reporter; Interview Coincides with Two Recent FDA Technology Clearances.

Business Editors and Health/Medical Writers

SUNNYVALE, Calif.--(BW HealthWire)--March 22, 2000

In the wake of two major FDA technology approvals, Thomas Prescott, CEO of Cardiac Pathways Corporation (Nasdaq:CPWY) was interviewed by Sam Stone of the Wall Street Reporter.

The interview, which occurred on Tuesday, March 21, can be accessed at http://www.wallstreetreporter.com/ and will remain on the Wall Street Reporter Site through Monday, March 27, 2000.

In the interview, Prescott discusses a number of Cardiac Pathway's corporate and technological initiatives, in particular, the company's stunning corporate turnaround.

In addition, Prescott provides a history and overview of the company, its newly appointed management team, its revolutionary technology platforms and disposable catheters in the treatment of cardiac arrythmia disorders as well as insight into the evolving Electrophysiology sector, Cardiac Pathway's primary market and user base.

Cardiac Pathways develops manufactures and markets minimally invasive systems to diagnose and treat cardiac tachyarrhythmias (abnormally rapid heart rhythms). The company is a pioneer and leader in the development of complete integrated mapping and ablation systems for the diagnosis and treatment of heart rhythm disturbances.

Wall Street Reporter is an information source for professional investors seeking successful new investment ideas and who demand an unbiased, unscripted, first-hand perspective that enables them to make informed investment decisions.

In addition to the Website, Wall Street Reporter Magazine is read by over 25,000 stockbrokers, portfolio managers, analysts and sophisticated investors. Wall Street Reporter does not provide recommendations or selling advice. Additionally, the interview with Prescott is a free service provided by Wall Street Reporter.